跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
GLP-1 receptor agonist (type 2 diabetes)
首页
药物
GLP-1 receptor agonist (type 2 diabetes)
GLP-1 receptor agonist (type 2 diabetes)
未知生产厂商
订阅
生成 AI 研报
Share to Twitter
Share to Facebook
Share to LinkedIn
Share to Reddit
摘要
临床试验
审批记录
专利
每项发明一条，涵盖美国、欧洲、PCT 与中国的同族专利。
GLP-1 RECEPTOR AGONISTS AND THEIR MEDICAL USE
申请人: AMGEN INC
优先权: 2024
WO
COMPOSITIONS COMPRISING AT LEAST AN AMYLIN RECEPTOR AGONIST AND A GLP-1 RECEPTOR AGONIST
申请人: ADOCIA
优先权: 2020
CN
EP
2 件公开
LONG ACTING GLUCAGON LIKE POLYPEPTIDE-1 (GLP-1) RECEPTOR AGONISTS AND METHODS OF USE
申请人: I2O THERAPEUTICS INC
优先权: 2020
CN
EP
US
WO
6 件公开
TREATMENT OF ADULTS WITH OVERWEIGHT OR OBESITY WITH OR WITHOUT WEIGHT-RELATED COMORBIDITIES
申请人: CARMOT THERAPEUTICS INC
优先权: 2023
CN
EP
US
WO
4 件公开
GLP-1 and GIP dual agonist fusion proteins
申请人: SHANGHAI MINWEI BIOTECHNOLOGY CO LTD
优先权: 2023
CN
Peptides acting as both GLP-1 receptor agonists and glucagon receptor antagonists and their pharmacological methods of use
申请人: PAN CLARK
优先权: 2002
US
2 件公开
Methods of treating type 2 diabetes with peptides acting as both GLP-1 receptor agonists and glucagon receptor antagonists
申请人: BAYER PHARMACEUTICALS CORP
优先权: 2003
US
3 件公开
Peptides acting as both GLP-1 receptor agonists and glucagon receptor antagonists and their pharmacological methods of use
申请人: BAYER PHARMACEUTICALS CORP
优先权: 2004
US
11 件公开
药物
反馈
